Atomoxetine for treatment of marijuana dependence: A report on the efficacy and high incidence of gastrointestinal adverse events in a pilot study

Drug and Alcohol Dependence

Volumn 94, Issue 1-3, 2008, Pages 254-257

  Tirado, Carlos F ^a   Goldman, Marina ^b   Lynch, Kevin ^b   Kampman, Kyle M ^b   Obrien, Charles P ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

ADHD; Atomoxetine; Marijuana dependence

Indexed keywords

ATOMOXETINE; CANNABIS;

ADULT; ARTHRALGIA; ARTICLE; CANNABIS ADDICTION; CLINICAL ARTICLE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INCIDENCE; INSOMNIA; LOOSE FECES; MALE; NAUSEA; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; UROGENITAL TRACT DISEASE; VOMITING; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ADULT; FEASIBILITY STUDIES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INCIDENCE; MALE; MARIJUANA ABUSE; PILOT PROJECTS; PROPYLAMINES;

CANNABIS; CANNABIS SATIVA;

EID: 39149110601     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2007.10.020     Document Type: Article

References (25)

1. Beck A.T., Epstein N., Brown G., and Steer R.A. An inventory for measuring clinical anxiety: psychometric properties. J. Consult. Clin. Psychol. 56 (1988) 893-897
2. Beck A.T., and Rickels K. Assessment of depression: the depression inventory. Modern Problems Pharmacopsychiatry 7 (1974) 151
3. Budney A.J., Higgins S.T., and Radonovich K.J. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J. Consult. Clin. Psychol. 68 (2000) 1051-1061
4. Budney A.J., Hughes J.R., Moore B.A., and Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am. J. Psychiatry 161 (2004) 1967-1977
5. Budney A.J., Vandrey R.G., Hughes J.R., Moore B.A., and Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend. 86 (2007) 22-29
6. Croci T., Manara L., Aureggi G., Guagnini F., Rinaldi-Carmona M., Maffrand J.P., Le Fur G., Mukenge S., and Ferla G. In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br. J. Pharmacol. 125 (1998) 1393-1395
7. Dennis M., Godley S.H., Diamond G., Tims F.M., Babor T., Donaldson J., Liddle H., Titus J.C., Kaminer Y., Webb C., Hamilton N., and Funk R. The Cannabis Youth Treatment (CYT) Study: main findings from two randomized trials. [see comment]. J. Subst. Abuse Treat. 27 (2004) 197-213
8. Haney M., Hart C.L., Vosburg S.K., Nasser J., Bennett A., Zubaran C., and Foltin R.W. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 29 (2004) 158-170
9. Haney M., Hart C.L., Ward A.S., and Foltin R.W. Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology (Berl.) 165 (2003) 157-165
10. Haney M., Ward A.S., Comer S.D., Hart C.L., Foltin R.W., and Fischman M.W. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology (Berl.) 155 (2001) 171-179
11. Huestis M.A., Gorelick D.A., Heishman S.J., Preston K.L., Nelson R.A., Moolchan E.T., and Frank R.A. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. [see comment]. Arch. Gen. Psychiatry 58 (2001) 322-328
12. Izzo A.A., Mascolo N., and Capasso F. Forgotten target for marijuana: the endocannabinoid system in the gut. [comment]. Trends Pharmacol. Sci. 21 (2000) 372-373
13. Klingberg T., Fernell E., Olesen P.J., Johnson M., Gustafsson P., Dahlstrom K., Gillberg C.G., Forssberg H., and Westerberg H. Computerized training of working memory in children with ADHD-a randomized, controlled trial. J. Am. Acad. Child Adolesc. Psychiatry 44 (2005) 177-186
14. Krain A.L., and Castellanos F.X. Brain development and ADHD. Clin. Psychol. Rev. 26 (2006) 433-444
15. Kratochvil C.J., Wilens T.E., and Upadhyaya H. Pharmacological management of a youth with ADHD, marijuana use, and mood symptoms. J. Am. Acad. Child Adolesc. Psychiatry 45 (2006) 1138-1141
16. Levin F.R., McDowell D., Evans S.M., Nunes E., Akerele E., Donovan S., and Vosburg S.K. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am. J. Addict. 13 (2004) 21-32
17. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., Pettinati H., and Argeriou M. The fifth edition of the addiction severity index. J. Subst. Abuse Treat. 9 (1992) 199-213
18. McRae A.L., Brady K.T., and Carter R.E. Buspirone for treatment of marijuana dependence: a pilot study. Am. J. Addict. 15 (2006) 404
19. Pope H.G., Gruber A., and Yurgelun-Todd D. The residual neuropsychological effects of cannabis: the current status of research. Drug. Alcohol Depend. 38 (1995) 25-34
20. Ramaekers J.G., Kauert G., van Ruitenbeek P., Theunissen E.L., Schneider E., and Moeller M.R. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 31 (2006) 2296-2303
21. SAMHSA, 2005. Results from the 2004 National Survey on Drug Use and Mental Health. DHHS Publication no. SMA 05-4062 NSDUH Series H-28.
22. Sobell L., and Sobell M. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Allen L.A. (Ed). Measuring Alcohol Consumption (1992), The Humana Press
23. Solowij N., Stephens R.S., Roffman R.A., Babor T., Kadden R., Miller M., Christiansen K., McRee B., and Vendetti J. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287 (2002) 1123-1131
24. Stephens R.S., Roffman R.A., and Curtin L. Comparison of extended versus brief treatments for marijuana use. J. Consult. Clin. Psychol. 5 68 (2000) 898-908
25. Wilens T.E. Attention deficit hyperactivity disorder and substance use disorders. Am. J. Psychiatry 163 (2006) 2059-2063